Dolutegravir + Rilpivirine bulk supplier for pharma manufacturers

Dolutegravir + Rilpivirine 50 mg / 25 mg Suppliers & Bulk Manufacturers

Q: What is Dolutegravir + Rilpivirine used for?

Dolutegravir and rilpivirine are used together as a complete two-drug regimen for the treatment of HIV-1 infection in adults. It is prescribed for patients who are already virologically suppressed on a stable antiretroviral therapy and want to switch to a simpler regimen. The combination maintains viral suppression and helps reduce pill burden.

Q: What is Dolutegravir + Rilpivirine made from?

It is made from Dolutegravir, an integrase strand transfer inhibitor, and Rilpivirine, a non-nucleoside reverse transcriptase inhibitor. Together, these two agents block HIV replication through different mechanisms, providing effective dual therapy.

Q: What is Dolutegravir + Rilpivirine trade name?

The trade name for this combination is Juluca.

Q: What company makes Dolutegravir + Rilpivirine?

Juluca is manufactured by ViiV Healthcare in collaboration with Janssen Therapeutics, which provides the rilpivirine component.

Q: What is generic name of Dolutegravir + Rilpivirine?

The generic name is Dolutegravir + Rilpivirine.

Q: Where is Dolutegravir + Rilpivirine manufactured?

It is manufactured in the UK and Europe by ViiV Healthcare, with global distribution, and generic versions are produced in India by licensed manufacturers for developing markets.

Available Forms: Tablet

Available Strengths: 50 mg / 25 mg

Reference Brands: Juluca(EU & US)

Category: Anti Viral

Dolutegravir + Rilpivirine, sold as Juluca, is a once-daily, two-drug HIV-1 maintenance therapy for virologically suppressed adults. It offers effective viral suppression with fewer side effects and is approved by the FDA and EMA.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Dolutegravir + Rilpivirine? List it or send an offer →

Product Description:

Dolutegravir + Rilpivirine, marketed as Juluca, is a once-daily, two-drug regimen for the maintenance treatment of HIV-1 infection. It combines Dolutegravir, an integrase strand transfer inhibitor (INSTI), and Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), to effectively suppress HIV replication. Approved by the US FDA and EMA, Juluca is intended for adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure. Juluca offers a simplified treatment option with fewer drugs, reduced side effects, and excellent tolerability, making it ideal for long-term HIV management.

Dolutegravir + Rilpivirine — third party manufacturing & bulk supply

Dolutegravir + Rilpivirine 50 mg / 25 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Dolutegravir + Rilpivirine is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Dolutegravir + Rilpivirine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Dolutegravir + Rilpivirine →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing